维奈克拉联合卡非佐米和地塞米松治疗复发/难治多发性骨髓瘤的2期研究
该2期剂量递增研究评估维奈克拉联合卡非佐米和地塞米松(VenKd)在复发/难治多发性骨髓瘤(RRMM)成人患者中的安全性、耐受性、药代动力学和抗肿瘤活性。VenKd耐受良好,在RRMM中显示有前景的缓解率,t(11;14)患者缓解更佳。
要点
- VenKd在RRMM中总缓解率80%,t(11;14)患者达92%。
- 完全缓解或更好率41%,中位无进展生存期22.8个月。
- 常见治疗中出现的不良事件为腹泻、乏力、恶心和淋巴细胞减少。
核心结论
- VenKd在RRMM患者中耐受良好,并显示出有前景的缓解率,t(11;14)患者缓解更佳。
主要发现
- 总缓解率为80%,t(11;14)患者(n=13)为92%,无t(11;14)患者(n=36)为75%。
- 完全缓解或更好率为41%,中位无进展生存期为22.8个月。
- 最常见治疗中出现的不良事件为腹泻(65%)、乏力(47%)、恶心(47%)和淋巴细胞减少(35%)。
- 26例(53%)患者发生严重不良事件,3例治疗中出现死亡,其中1例被认为与治疗相关。
关键数值与推荐
- 剂量探索队列:口服维奈克拉400或800 mg每日,联合静脉卡非佐米27、56或70 mg/m2及口服地塞米松20或40 mg。
- 扩展队列:维奈克拉800 mg、卡非佐米70 mg/m2、地塞米松40 mg。
临床怎么用
- VenKd可作为复发/难治多发性骨髓瘤的治疗选择,尤其对t(11;14)患者可能缓解更佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proteins in the antiapoptotic B-cell lymphoma 2 (BCL-2) family play a role in the pathophysiology of multiple myeloma (MM). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis of MM cells, and its efficacy may be potentiated through combination with agents that increase BCL-2 dependency or have complementary mechanisms of action. The safety, tolerability, pharmacokinetics, and antitumor activity of venetoclax in combination with carfilzomib and dexamethasone (VenKd) in adults with relapsed/refractory MM (RRMM) were investigated in this phase 2 dose-escalation study. Oral venetoclax (400 or 800 mg) was administered daily in combination with intravenous carfilzomib (27, 56, or 70 mg/m2) and oral dexamethasone (20 or 40 mg) in 4 dose-finding cohorts. The expansion cohort received venetoclax 800 mg, carfilzomib 70 mg/m2, and dexamethasone 40 mg. Forty-nine patients received treatment. Median prior lines of therapy was 1 (range, 1-3), and median time in the study was 27 months. The most common treatment-emergent adverse events were diarrhea (65%), fatigue (47%), nausea (47%), and lymphopenia (35%). Serious adverse events occurred in 26 (53%) patients. Of 3 treatment-emergent deaths, 1 was considered treatment related. The overall response rate was 80% in all patients, 92% in patients with t(11;14) (n = 13), and 75% in patients without (n = 36). The rate of complete response or better was 41%. Median progression-free survival was 22.8 months. Treatment with VenKd was well tolerated and showed promising response rates in this RRMM patient population, with greater responses observed in patients with t(11;14). This trial is registered at www.clinicaltrials.gov as #NCT02899052.
引用
- Costa LJ, Davies FE, Monohan GP, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021. PMID: 34470049. doi:10.1182/bloodadvances.2020004146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。